Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial

Neurology

Volumn 78, Issue 14, 2012, Pages 1069-1078

  Coles, A J ^a   Fox, E ^b   Vladic, A ^c   Gazda, S K ^d   Brinar, V ^e   Selmaj, K W ^f   Skoromets, A ^g   Stolyarov, I ^h   Bass, A ⁱ   Sullivan, H ^j   Margolin, D H ^k   Lake, S L ^k   Moran, S ^k   Palmer, J ^k   Smith, M S ^l   Compston, D A S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Central Texas Neurology Consultants   (United States)

^c Croatian Academy of Medical Sciences   (Croatia)

^d Integra Clinical Research   (United States)

^e UNIVERSITY OF ZAGREB   (Croatia)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^h RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

ⁱ Neurology Center of San Antonio   (United States)

^j Saint Mary's Health Care   (United States)

^k GENZYME CORPORATION   (United States)

^l Research Pharmaceutical Services Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE;

ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; CLINICAL TRIAL; DISABILITY; DRUG EFFICACY; DRUG SAFETY; FLU LIKE SYNDROME; FOLLOW UP; GOODPASTURE SYNDROME; HERPES SIMPLEX; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYCOSIS; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; THYROID DISEASE; TREATMENT DURATION; VIRUS REACTIVATION;

EID: 84860780657     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31824e8ee7     Document Type: Article

References (15)

1. Cox AL, Thompson SAJ, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005;35:3332-3342. (Pubitemid 41672537)
2. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009;119:2052-2061.
3. Thompson SAJ, Jones JL, Cox AL, Compston DAS, Coles AJ. B-cell reconstitution and BAFF after alemtuzumab. J Clin Immunol 2010;30:99-105.
4. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy. J Neurol 2006;253:98-108. (Pubitemid 43157395)
5. Fox EJ, Sullivan HC, Gazda SK, et al. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis Eur J Neurol 2012;19: 307-311.
6. CAMMS223 Trial Investigators. Alemtuzumab vs. interferon 1a in early multiple sclerosis. N Engl J Med 2008; 359:1786-1801.
7. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon 1a in early relapsing-remitting multiple sclerosis: Post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011;10:338-348.
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452. (Pubitemid 14237132)
9. Little RJA, Rubin DB. Statistical Analysis with Missing Data. New York: John Wiley; 1987.
10. Rotnitzky A, Robins JM, Scharftstein DO. Semiparametric regression for repeated outcomes with nonignorable nonresponse. J Am Stat Assoc 1998;93:1321-1339. (Pubitemid 128385545)
11. Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005;20:748-753. (Pubitemid 41141008)
12. Meyer D, Coles AJ, CAMMS223 Study Group. Case report of anti-glomerular basement membrane disease following alemtuzumab treatment. Poster presented at the European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting; October 13-16, 2010; Gothenburg, Sweden.
13. Vogel WH. Infusion reactions: Diagnosis, assessment, and management. Clin J Oncol Nurs 2010;14:E10-E21.
14. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-609.
15. Clatworthy MR, Wallin EF, Jayne DR. Anti-glomerular basement membrane disease after alemtuzumab. N Engl J Med 2008;359:768-769.